AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21937177 — intervention group
Group type: EXPERIMENTAL
Intervention: CT/US fusion imaging during pRFA (group 2)
Number of subjects: 37
Study 21937177 — intervention group
Group type: EXPERIMENTAL
Intervention: CT/US fusion imaging during pRFA (group 3)
Number of subjects: 37
Study 21937177 — intervention group
Group type: EXPERIMENTAL
Intervention: CT/US fusion imaging
Number of subjects: 37
Study 20444534 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest 2mg
Number of subjects: 198
Study 20444534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 17712070 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand relaparotomy strategy
Number of subjects: 232
Study 17712070 — intervention group
Group type: COMPARATOR
Intervention: Planned relaparotomy strategy
Number of subjects: 232
Study 15642557 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 0
Study 15642557 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 12396296 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid Gaviscon (20 mL)
Number of subjects: 6
Study 12396296 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaviscon Advance (10 mL)
Number of subjects: 6
Study 9932999 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser peripheral retinal photocoagulation
Number of subjects: 103
Study 8675854 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous pushing
Number of subjects: 32
Study 8675854 — intervention group
Group type: COMPARATOR
Intervention: Directed pushing
Number of subjects: 32
Study 2114036 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 500 mg/kg
Number of subjects: 500
Study 2114036 — intervention group
Group type: COMPARATOR
Intervention: Placebo (albumin-saline)
Number of subjects: 500
Study 7284972 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly oral 5-fluorouracil (5-FU)
Number of subjects: 51
Study 7284972 — intervention group
Group type: COMPARATOR
Intervention: Weekly intravenous 5-fluorouracil (5-FU)
Number of subjects: 51
Study 30599367 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-delivered attention bias modification (HD-ABM) training
Number of subjects: 82
Study 30599367 — intervention group
Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 82
Study 30599367 — intervention group
Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 82
Study 27442139 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagram-assisted interview (diagram-first condition)
Number of subjects: 287
Study 27442139 — intervention group
Group type: COMPARATOR
Intervention: Conventional interview (conventional-first condition)
Number of subjects: 287
Study 24243484 — intervention group
Group type: EXPERIMENTAL
Intervention: VADSS
Number of subjects: 31
Study 24243484 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 31
Study 23974035 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss only treatment (WL)
Number of subjects: 252
Study 23974035 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AT) + weight loss (WL)
Number of subjects: 252
Study 23974035 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RT) + weight loss (WL)
Number of subjects: 252
Study 21329622 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide tablets
Number of subjects: 302
Study 21329622 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide capsules
Number of subjects: 302
Study 19433701 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to small branded promotional items for Lipitor (atorvastatin)
Number of subjects: 352
Study 19433701 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exposure to promotional items)
Number of subjects: 352
Study 19433701 — intervention group
Group type: EXPERIMENTAL
Intervention: University of Miami students
Number of subjects: 352
Study 19433701 — intervention group
Group type: COMPARATOR
Intervention: University of Pennsylvania students
Number of subjects: 352
Study 16724678 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) at a dose of 2400 mg/day for 12 weeks
Number of subjects: 20
Study 16724678 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study 16724678 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 20
Study 15019882 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine functional testing
Number of subjects: 348
Study 15019882 — intervention group
Group type: COMPARATOR
Intervention: Selective functional testing
Number of subjects: 348
Study 11357851 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (enoxaparin)
Number of subjects: 314
Study 11357851 — intervention group
Group type: COMPARATOR
Intervention: Dextran 70
Number of subjects: 314
Study 9143868 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled diffusion diltiazem (180 mg taken in the morning)
Number of subjects: 7
Study 9143868 — intervention group
Group type: COMPARATOR
Intervention: Conventional release diltiazem (90 mg taken twice daily)
Number of subjects: 7
Study 7956413 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol (1 mL 0.5% in 3 mL saline solution)
Number of subjects: 8
Study 7956413 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (4 mL)
Number of subjects: 8
Study 3238472 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose HB vaccine (Group A, 69 infants)
Number of subjects: 204
Study 3238472 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose HB vaccine (Group B, 70 infants)
Number of subjects: 204
Study 3238472 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group (Group C, 65 infants)
Number of subjects: 204
Study 29560766 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt fascial opening
Number of subjects: 123
Study 29560766 — intervention group
Group type: COMPARATOR
Intervention: Sharp fascial opening
Number of subjects: 123
Study 27208498 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg brexpiprazole + ADT
Number of subjects: 0
Study 27208498 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg brexpiprazole + ADT
Number of subjects: 0
Study 27208498 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg brexpiprazole + ADT
Number of subjects: 0
Study 27208498 — intervention group
Group type: COMPARATOR
Intervention: Placebo + ADT
Number of subjects: 0
Study 24293166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon
Number of subjects: 110
Study 24293166 — intervention group
Group type: COMPARATOR
Intervention: Open‐irrigated tip RF catheter
Number of subjects: 110
Study 24293166 — intervention group
Group type: COMPARATOR
Intervention: Visually guided laser balloon
Number of subjects: 110
Study 24293166 — intervention group
Group type: COMPARATOR
Intervention: Open‐irrigated tip RF catheter with contact‐force‐sensing technology
Number of subjects: 110
Study 23758673 — intervention group
Group type: EXPERIMENTAL
Intervention: Kivia powder (5.5 g daily for four weeks)
Number of subjects: 87
Study 23758673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 20010135 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based aquatic exercise program (n = 125)
Number of subjects: 249
Study 20010135 — intervention group
Group type: COMPARATOR
Intervention: Usual activity levels (Control group, n = 124)
Number of subjects: 249
Study 18164276 — intervention group
Group type: EXPERIMENTAL
Intervention: Feature-Positive Effect (FPE) test
Number of subjects: 53
Study 17312823 — intervention group
Group type: EXPERIMENTAL
Intervention: MCCU (mobile coronary care unit) group
Number of subjects: 248
Study 17312823 — intervention group
Group type: COMPARATOR
Intervention: Hospital group
Number of subjects: 248
Study 17312823 — intervention group
Group type: EXPERIMENTAL
Intervention: MCCU group
Number of subjects: 248
Study 12939876 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenazid (0.5 g daily for 2 months)
Number of subjects: 49
Study 12939876 — intervention group
Group type: COMPARATOR
Intervention: Routine antituberculous chemotherapy regimen including isoniazid
Number of subjects: 49
Study 10617523 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem solving treatment
Number of subjects: 0
Study 10617523 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 0
Study 10617523 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of problem solving treatment and antidepressant medication
Number of subjects: 0
Study 10617523 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem solving treatment delivered by practice nurses
Number of subjects: 0
Study 10617523 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem solving treatment delivered by general practitioners
Number of subjects: 0
Study 9169747 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-cell pertussis vaccine (wP)
Number of subjects: 5
Study 9169747 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (aP-SB)
Number of subjects: 5
Study 9169747 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (aP-CB)
Number of subjects: 5
Study 9169747 — intervention group
Group type: COMPARATOR
Intervention: Control group (DT or unresponsive pertussis vaccine recipients)
Number of subjects: 5
Study 9169747 — intervention group
Group type: COMPARATOR
Intervention: Prevaccination children
Number of subjects: 5
Study 8466237 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nebulised budesonide
Number of subjects: 36
Study 8466237 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 36
Study 3512507 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (methicillin 2 g and netilmicin 200 mg, three doses)
Number of subjects: 141
Study 3512507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 29328860 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 1918
Study 29328860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1918
Study 27681077 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (daily capsule containing Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum at 2×10^9 CFU/g each plus 800 mg inulin) for 6 weeks
Number of subjects: 70
Study 27681077 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 70
Study 27681077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 24947504 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of chlorogenic acids (412 μmol)
Number of subjects: 11
Study 24947504 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose of chlorogenic acids (635 μmol)
Number of subjects: 11
Study 24947504 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of chlorogenic acids (795 μmol)
Number of subjects: 11
Study 22544046 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine 4 mg three times per day for 12 weeks
Number of subjects: 25
Study 22544046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 20573567 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedra dry extract (1g once per day for 14 days)
Number of subjects: 20
Study 18208639 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to mortality-related information about the risks of binge drinking (Study 2)
Number of subjects: 393
Study 18208639 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to information about the mortality-related risks of binge drinking (Study 1)
Number of subjects: 393
Study 15855489 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg infusion of isoniazid
Number of subjects: 18
Study 15855489 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral single dose of isoniazid
Number of subjects: 18
Study 15855489 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg oral single dose of isoniazid
Number of subjects: 18
Study 15855489 — intervention group
Group type: EXPERIMENTAL
Intervention: NAT2 genotype assessment
Number of subjects: 18
Study 15855489 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of variance
Number of subjects: 18
Study 11943795 — intervention group
Group type: EXPERIMENTAL
Intervention: Community based screening programme for melanoma (3 years duration)
Number of subjects: 560000
Study 11943795 — intervention group
Group type: COMPARATOR
Intervention: Normal practice (control group)
Number of subjects: 560000
Study 10606106 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 336
Study 10606106 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 336
Study 10606106 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-induced reversible thallium defects (both PTCA and CABG)
Number of subjects: 336
Study 8524425 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate suspension 2 g daily (twice daily for 6 months)
Number of subjects: 184
Study 8524425 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily for 6 months)
Number of subjects: 184
Study 1771280 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 31
Study 1771280 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone-Isoflurane
Number of subjects: 31
Study 7048519 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalosporin (oral)
Number of subjects: 20
Study 30507832 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) headset with live holographic orientation feedback
Number of subjects: 24
Study 30507832 — intervention group
Group type: COMPARATOR
Intervention: Hands-on training by an expert surgeon
Number of subjects: 24
Study 30507832 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) headset
Number of subjects: 24
Study 29384023 — intervention group
Group type: EXPERIMENTAL
Intervention: ProFiL program
Number of subjects: 442
Study 29384023 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) group
Number of subjects: 442
Study 27206939 — intervention group
Group type: COMPARATOR
Intervention: Evacetrapib 500 mg/d
Number of subjects: 393
Study 27206939 — intervention group
Group type: COMPARATOR
Intervention: Evacetrapib plus statins (100 mg evacetrapib + simvastatin 40 mg/d, atorvastatin 20 mg/d, or rosuvastatin 10 mg/d)
Number of subjects: 393
Study 27206939 — intervention group
Group type: COMPARATOR
Intervention: Evacetrapib plus statins
Number of subjects: 393
Study 27206939 — intervention group
Group type: COMPARATOR
Intervention: Evacetrapib alone or with statins
Number of subjects: 393
Study 25052061 — intervention group
Group type: EXPERIMENTAL
Intervention: MEmory Specificity Training (MEST)
Number of subjects: 60
Study 25052061 — intervention group
Group type: COMPARATOR
Intervention: Education and Support (ES)
Number of subjects: 60
Study 22271078 — intervention group
Group type: EXPERIMENTAL
Intervention: IVC filter
Number of subjects: 141
Study 22271078 — intervention group
Group type: COMPARATOR
Intervention: No filter (control group)
Number of subjects: 141
Study 19131401 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg daily
Number of subjects: 201
Study 19131401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 17553812 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg/day)
Number of subjects: 78
Study 17553812 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam/amoxicillin-clavulanate
Number of subjects: 78
Study 17553812 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 78
Study 15208125 — intervention group
Group type: EXPERIMENTAL
Intervention: iodixanol
Number of subjects: 200
Study 15208125 — intervention group
Group type: COMPARATOR
Intervention: iohexol
Number of subjects: 200
Study 12701645 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone Diskhaler (Flutide)
Number of subjects: 246
Study 12701645 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone (BDI)
Number of subjects: 246
Study 9715790 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ANG II (400 microg)
Number of subjects: 12
Study 9715790 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ANG II (2.5 microg)
Number of subjects: 12
Study 9715790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7866465 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.2 MJ/d diet with exercise
Number of subjects: 118
Study 7866465 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.2 MJ/d diet
Number of subjects: 118
Study 7866465 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 118
Study 2555803 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (0.13 mg/kg)
Number of subjects: 9
Study 2555803 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (100 mg)
Number of subjects: 9
Study 2555803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 782808 — intervention group
Group type: EXPERIMENTAL
Intervention: Sisomicin
Number of subjects: 12
Study 782808 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 12
Study 31446629 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar consumption restricted to less than 3% of total daily calories for 8 weeks
Number of subjects: 0
Study 31446629 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (control group)
Number of subjects: 0
Study 30925951 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery combined with GnRH agonist (GnRH‐a)
Number of subjects: 130
Study 30925951 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 130
Study 28188972 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercise with placebo
Number of subjects: 33
Study 28188972 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise with liraglutide
Number of subjects: 33
Study 28188972 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between groups
Number of subjects: 33
Study 28188972 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise with liraglutide and placebo
Number of subjects: 33
Study 25788492 — intervention group
Group type: EXPERIMENTAL
Intervention: BNC105P with everolimus (arm A)
Number of subjects: 139
Study 25788492 — intervention group
Group type: COMPARATOR
Intervention: Everolimus alone (arm B)
Number of subjects: 139
Study 23688546 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine (QIV)
Number of subjects: 105
Study 23688546 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose adjuvanted quadrivalent influenza vaccine (LD QIV-AS)
Number of subjects: 105
Study 23688546 — intervention group
Group type: COMPARATOR
Intervention: Trivalent influenza vaccine (TIV)
Number of subjects: 105
Study 23688546 — intervention group
Group type: COMPARATOR
Intervention: Low-dose adjuvanted trivalent influenza vaccine (LD TIV-AS)
Number of subjects: 105
Study 21047278 — intervention group
Group type: EXPERIMENTAL
Intervention: SVH test in healthy subjects
Number of subjects: 40
Study 21047278 — intervention group
Group type: EXPERIMENTAL
Intervention: SVH test in Meniere's patients
Number of subjects: 40
Study 21047278 — intervention group
Group type: COMPARATOR
Intervention: oVEMP test in healthy subjects
Number of subjects: 40
Study 21047278 — intervention group
Group type: EXPERIMENTAL
Intervention: oVEMP test in Meniere's patients
Number of subjects: 40
Study 21047278 — intervention group
Group type: COMPARATOR
Intervention: cVEMP test in healthy subjects
Number of subjects: 40
Study 21047278 — intervention group
Group type: EXPERIMENTAL
Intervention: cVEMP test in Meniere's patients
Number of subjects: 40
Study 21047278 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between SVH and oVEMP tests
Number of subjects: 40
Study 21047278 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between SVH and cVEMP tests
Number of subjects: 40
Study 17904221 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine addicts
Number of subjects: 50
Study 17904221 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine addicts with childhood neglect
Number of subjects: 50
Study 17904221 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 50
Study 17931320 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychosocial intervention (2 hours per week for 2 months)
Number of subjects: 48
Study 17931320 — intervention group
Group type: COMPARATOR
Intervention: Routine unit care and self-care booklet
Number of subjects: 48
Study 15824913 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 100 microg kg‐1 followed by pancuronium 15 microg kg‐1 (group 1)
Number of subjects: 20
Study 15824913 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium 15 microg kg‐1 followed by mivacurium 100 microg kg‐1 (group 2)
Number of subjects: 20
Study 12234948 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial vitamin C (24 mg/min)
Number of subjects: 8
Study 12234948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 12234948 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C alone in control experiments
Number of subjects: 8
Study 9653567 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraperitoneal incision in aorto-iliac occlusive disease
Number of subjects: 60
Study 9653567 — intervention group
Group type: COMPARATOR
Intervention: Transperitoneal incision in aorto-iliac occlusive disease
Number of subjects: 60
Study 9653567 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneal posterolateral approach in aneurysm patients
Number of subjects: 60
Study 8088389 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar epidural anaesthesia (EPI; n = 9) continued for 24 hours postoperatively
Number of subjects: 18
Study 8088389 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GA; n = 9) followed by intramuscular analgesics
Number of subjects: 18
Study 8088389 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GA; n = 9)
Number of subjects: 18
Study 8088389 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar epidural anaesthesia (EPI; n = 9)
Number of subjects: 18
Study 2686742 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 30
Study 2686742 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen
Number of subjects: 30